

TEST CHANGE

Drug Panel 9, Urine - Screen with Reflex to Confirmation/Quantitation

0092186, CDASU 9

Specimen Requirements:

Patient Preparation:

Collect: Random urine.

Specimen Preparation: Transfer 8 mL urine with no additives or preservatives to ARUP Standard Transport Tubes. (Min: 4 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Specimens exposed to repeated freeze/thaw cycles.

Remarks:

Stability: Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

Methodology: Qualitative Enzyme Multiplied Immunoassay Technique/
Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed: Sun-Sat

Reported: 1-4 days

Note: If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply. To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).

CPT Codes: 80307; if reflexed, add 80325; 80345; 80346; 80349; 80353; 80358; 80359; 80361; 80365; 80367; 83992 (Reflexed Alt Code: G0480)

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results. The following opioids are not detected in this test: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.

For medical purposes only; not valid for forensic use.

Reference Interval:

[Effective June 1, 2015](#)

Drugs Covered and Cutoff Concentrations	
Drugs/Drug Classes	Screen
THC (Cannabinoids)	5020 ng/mL
Cocaine	150 ng/mL
Opiates	300 ng/mL
Oxycodone	100 ng/mL
Phencyclidine	25 ng/mL
Amphetamines	300 ng/mL
MDMA (Ecstasy)	500 ng/mL
Barbiturates	200 ng/mL
Benzodiazepines	200 ng/mL
Methadone	150 ng/mL
Propoxyphene	300 ng/mL